New Accelerated AI Cancer Diagnostics Platform Shortens Time to Diagnosis

A diagnostic solution for non-small cell lung cancer dramatically reduces the diagnostic period from several weeks to mere minutes. By harnessing the power of artificial intelligence (AI), the integrated platform instantly processes digitized images of stained pathology slides, identifying actionable biomarkers in just a short time. This allows for the prompt initiation of personalized treatments, potentially leading to better patient outcomes.

This latest advancement in cancer diagnostics is the result of the collaboration between Sheba Medical Center (Ramat Gan, Israel) and Imagene (Tel Aviv, Israel) that led to the development of a rapid AI-based molecular profiling algorithm capable of identifying actionable biomarkers using only digital biopsy images. Sheba Medical Center has deployed the new accelerated, AI-powered cancer diagnostics research platform to improve patient diagnosis, treatment and outcomes.

The AI solution employs an algorithm to detect actionable biomarkers of non-small cell lung cancer. The algorithm is applied directly to a digitized image of a conventionally stained pathology slide. Within minutes, it identifies the presence of actionable biomarkers in the tumor to offer vital information for enabling diagnostic and therapeutic decisions. The solution cuts the diagnostic time from three weeks to minutes, allowing treatment to be started much earlier.

“We have reached another significant milestone in digital pathology with this ability to detect biomarkers by AI,” said Prof. Iris Barshack, Head of the Pathology Institute at Sheba Medical Center. “The use of deep learning algorithms is changing the world of diagnosis, and in certain cases can drastically shorten the cost and time to treatment. I am excited to hear about the growing number of patients who were able to receive rapid diagnoses and treatment using our new service.”

“We are very proud to be part of this incredibly important initiative by Prof. Barshack to facilitate an accelerated program for rapid diagnosis of cancer patients,” said Dean Bitan, Co-founder and CEO of Imagene. “It takes an innovative approach and openness to new and advanced technologies to drive cancer research and advanced cancer care. We believe this program will showcase the importance of rapid molecular profiling within the clinical workflow.”

"AI is already transforming the field of healthcare and oncology specifically. ARC is proud to be a part of this collaborative achievement in precision medicine that will have a significant impact in global health,” said Prof. Eyal Zimlichman, Chief Transformation Officer and Chief Innovation Officer at Sheba Medical Center and Director and Founder of ARC Innovation.

Related Links:
Imagene
Sheba Medical Center 

Visit expo >

Platinum Supplier

ADAMTS-13 Protease Activity Test

ATS-13 Activity Assay

Gold Supplier

COVID-19 Antigen Self-Test

Panbio COVID-19 Antigen Self-Test

New

Yellow Fever Virus Test

Yellow Fever Virus IgG – ELISA

New

Pipettors

Corning Lambda EliteTouch